Core Viewpoint - The research highlights the potential of genetically engineered human mesenchymal progenitor cells (SRC) to counteract aging in primates, suggesting a new paradigm for anti-aging cell therapy [2][12]. Group 1: Aging Mechanism and Cell Therapy - The study investigates the mechanisms of aging regulation and employs synthetic biology to reprogram longevity gene pathways, successfully creating SRC with triple resistance to aging, stress, and malignant transformation [3][7]. - SRC cells exhibit significant anti-aging activity and strong environmental adaptability, while also demonstrating excellent safety features to avoid tumorigenic risks post-transplantation [8]. Group 2: Experimental Results - In a 44-week trial involving elderly crab-eating macaques (equivalent to 60-70 years in human age), SRC therapy resulted in reduced systemic aging indicators, such as cellular senescence, chronic inflammation, and tissue degeneration, with no adverse reactions detected [10]. - Notably, SRC treatment improved brain structure and cognitive function, reversing the biological age of immature neurons by 6-7 years and oocytes by 5 years, as confirmed by machine learning-based aging clock analysis [10]. Group 3: Mechanism of Action - The restorative effects of SRC are partially attributed to their exosomes, which play a crucial role in promoting cellular rejuvenation, inhibiting chronic inflammation, and maintaining genomic and epigenomic stability, providing new insights into pathways for delaying systemic aging [10].

在大健康产业蓬勃发展的当下，梅花鹿产品凭借其独特的滋补与药用价值，在市场上愈发受到青睐。尊 禧鹿生物科技研究（湖北）院应运而生，专注于梅花鹿产品的全方位研究，尤其在质量检测与成分分析 领域成果斐然，为梅花鹿产业的健康发展筑牢根基。 深入剖析：解密成分奥秘 梅花鹿产品成分复杂，蕴含多种对人体有益的物质。为了深入了解这些成分，挖掘其潜在价值，尊禧鹿 生物科技研究（湖北）院组建了专业的研发团队，团队成员涵盖生物化学、药学、营养学等多领域专 家。 在对鹿茸的研究中，科研人员运用现代分离技术，先通过高效液相色谱（HPLC）对鹿茸提取物进行初 步分离，将性质相近的成分进行分组。随后，借助制备型高效液相色谱进一步提纯，获取高纯度的目标 成分。再通过质谱（MS）技术，精确测定各成分的分子量，并结合核磁共振（NMR）波谱，确定其化 学结构与组成。经过大量实验，研究发现，每 100 克鹿茸中，含有氨基酸总量高达 50 - 60 克，其中包 含人体必需的 8 种氨基酸；多肽含量约为 10 - 15 克，且不同分子量的多肽具有不同生物活性。此外， 还富含钙、磷、镁等矿物质以及小分子代谢物 "尿苷" 等。其中，"尿苷" 在动物实验中表 ...

神译局是36氪旗下编译团队，关注科技、商业、职场、生活等领域，重点介绍国外的新技 术、新观点、新风向。 编者按：40+人群如何科学延缓衰老？本文从神经生物学、新陈代谢角度切入，拆解晨间习惯对衰老的 深层影响，提供可落地的5大抗衰方案。让我们回归科学本质，用每一个日常选择来让细胞焕发新生 吧。文章来自编译。 你有没有怀疑过自己早上的习惯反而会让你老得更快？ 事实上，起床后第一个小时做的事，会直接影响你变衰老的速度。 明明睡够了8小时，醒来却像没睡过一样？跌跌撞撞爬起来喝咖啡刷手机，浑浑噩噩过一天？ 但你可能不知道——正是这些习惯让你越活越累、压力变大，甚至加速变老。 虽然听起来夸张，但你起床的方式、喝水习惯、动不动身子、早餐吃什么，都会实实在在影响你的精 力、皮肤状态和衰老速度。 如果做得不对，你会一整天都昏昏沉沉、皮肤暗黄、有气无力。如果做得对，不用花里胡哨的操作，就 能保持头脑清醒、容光焕发。 下面就来揪出5个常见错误（附解决办法），帮助你轻松开启活力满满的一天： 为什么每天起床都像没睡醒？ 睡了8小时还是困得睁不开眼，甚至想再睡8小时？ 这种似睡非睡的状态叫"睡眠惯性"——你的身体醒了，但大脑还没醒。部分 ...

Core Viewpoint - The ongoing dispute between renowned biologist Rao Yi and Kelun Pharmaceutical regarding the classification of ergothioneine as a "fake drug" has escalated, with Kelun asserting that ergothioneine is recognized internationally as a dietary supplement rather than a drug, thus negating the "fake drug" claim [1][12]. Company Response - On June 6, Kelun Pharmaceutical published a response on its official WeChat account, stating its commitment to clarify misunderstandings with rigorous scientific data and emphasizing that ergothioneine is a health management tool [1]. - Kelun cited various authoritative journals and clinical studies to support its claims about ergothioneine's benefits, including research from the Leibniz Institute and Harvard Medical School, which suggest ergothioneine can mediate healthy aging through dual mechanisms [6][9]. Market Reaction - Following the controversy, Kelun Pharmaceutical's stock price fell by 0.74% to 37.47 yuan per share, resulting in a market capitalization of 598.79 billion yuan [2]. Clinical Evidence - Kelun referenced multiple clinical trials conducted in Japan, Singapore, and Sweden, demonstrating ergothioneine's efficacy in areas such as sleep health, cognitive health, skin anti-aging, and cardiovascular health [7][9]. - The results of these trials were published in reputable journals, with three out of four being top-tier in their respective fields [9]. Regulatory Context - Ergothioneine has been recognized as a novel food supplement in several countries, including the U.S. and Japan, with the U.S. FDA granting it GRAS (Generally Recognized As Safe) status [9]. - However, it is noted that while the National Health Commission of China has accepted an application for ergothioneine as a new food ingredient, it has not yet been approved [9]. Scientific Debate - Rao Yi challenged Kelun's claims, stating that without approval from the National Medical Products Administration, the promotion of ergothioneine could be misleading or deceptive [5][12]. - Kelun responded by arguing that the approval process for drugs differs from that of dietary supplements, emphasizing that ergothioneine serves a different purpose in health management [12].

撰文丨王聪 编辑丨王多鱼 排版丨水成文 最近，关于 牛磺酸 的研究接连登上三大顶刊 Science 、 Cell 和 Nature ，这些研究揭示了 牛磺酸的新功 能—— 抗衰老 【1】 、 提高癌症治疗效果 【2】 、 抗肥胖 【3】 ，当然，也不都是好消息，今年 5 月份发 表在 Nature 上的一项则显示， 肿瘤微环境中的牛磺酸会促进白血病 【4】 。 2025 年 6 月 5 日，牛磺酸研究再次登上顶刊 Science ，来自美国国立卫生研究院国家老龄化研究所的研 究团队 ，发表了题为： Is taurine an aging biomarker? （牛磺酸是衰老标志物吗？） ， 直接质疑了牛磺 酸作为衰老的生物标志物的观点 【5】 。 该研究显示：1）成年期循环牛磺酸浓度不会随年龄增长而下降；2）个体间循环牛磺酸浓度的差异通常大 于其一生中的纵向变化，这限制了其作为衰老生物标志物的实用性；3）循环牛磺酸浓度与健康状况的功能 指标之间的关联取决于具体情境 （年龄、物种或队列） ——。 研究团队进一步得出结论—— 牛磺酸浓度与衰老之间没有明显关联，循环牛磺酸浓度也就不太可能成为一 种良好的衰老生物标志 ...

Core Viewpoint - The core controversy revolves around whether the product Ergotioneine capsules from Kelun Pharmaceutical is a dietary supplement or a "fake drug" as claimed by Peking University’s Rao Yi [1][4]. Group 1: Company Position - Kelun Pharmaceutical asserts that Ergotioneine is recognized internationally as a dietary supplement and not a drug, thus challenging the notion of it being labeled as a "fake drug" [1][4]. - The company emphasizes that the value and safety of Ergotioneine have been scientifically validated through various studies, including those published in top journals [2][3]. - Kelun Pharmaceutical calls for an objective industry perspective on emerging technologies to shift the nutrition and health industry from a marketing-driven approach to a science-driven one [1][6]. Group 2: Scientific Evidence - The company cites two studies published in "Cell Metabolism" demonstrating that Ergotioneine can significantly extend the lifespan of model organisms and improve their physical performance [2]. - Additional clinical research indicates that Ergotioneine may help reduce sleep difficulties, improve cognitive functions in patients with mild cognitive impairment, decrease skin wrinkles, and lower the risk of coronary artery disease [3]. - The safety of Ergotioneine has been established in toxicity tests and randomized controlled trials, with its acceptance as a new food supplement in developed countries [3]. Group 3: Market Performance - Despite the controversy, Kelun Pharmaceutical's Ergotioneine products continue to be sold, with prices ranging from 1,199 yuan to 4,476 yuan, and sales exceeding 18.83 million yuan as of June 5 [5].

Group 1 - A recent study from the University of California, San Diego, found that women with type 2 diabetes taking metformin have a 30% higher chance of living to 90 years or older compared to those using sulfonylureas [1] - Metformin is evolving from a traditional diabetes medication to a potential anti-aging treatment, with increasing evidence suggesting its role in longevity [1] - The study establishes a link between metformin monotherapy and the likelihood of living to 90 years or older, filling a research gap in this area [1] Group 2 - Key companies involved in metformin production include Koyuan Pharmaceutical, which produces metformin hydrochloride raw materials and tablets for type 2 diabetes treatment [2] - Another company, Teva Pharmaceutical, produces metformin sustained-release tablets that reduce liver glucose production and improve insulin sensitivity [2]

Core Viewpoint - The controversy surrounding Kelun Pharmaceutical and its chairman Liu Gexin has intensified due to allegations regarding the efficacy and regulatory status of its anti-aging product, Ergothioneine, which has not received official certification as a health product in China [1][2][4]. Financial Performance - In Q1 2025, Kelun Pharmaceutical reported a significant revenue decline of 29% year-on-year, totaling 4.39 billion yuan, while net profit plummeted by 43% to 584 million yuan, marking the worst quarterly performance in five years [5][6]. - The company's traditional infusion business revenue fell below 9 billion yuan, a record low, contributing to the overall financial downturn [5][6]. - The cash flow from operating activities also dropped over 60%, reaching 450 million yuan, indicating severe operational challenges [5]. Product Controversy - Ergothioneine, marketed as an anti-aging supplement, lacks regulatory approval and has not been substantiated by scientific evidence for its claimed benefits, raising compliance and ethical concerns [2][3][4]. - The product is being sold through cross-border e-commerce channels, exploiting regulatory differences between domestic and international markets [3][4]. Business Strategy and Challenges - The chairman has positioned the anti-aging sector as the "fourth entrepreneurial venture" for the company, following its traditional infusion and antibiotic businesses, aiming to create an ecosystem around anti-aging products [6][7]. - The subsidiary, Chuaning Biological, which was expected to drive growth through synthetic biology, has seen its revenue contribution remain minimal, indicating slow progress in its transformation strategy [7]. Market Environment - The pharmaceutical industry is facing significant challenges due to stringent government policies, such as the "limit on antibiotics" directive, which has adversely affected the infusion market and overall demand [6][7]. - Despite the decline in traditional business, non-infusion segments (generic and innovative drugs) showed some growth, but this was insufficient to offset the losses from the core infusion business [6].

Group 1 - The fifth "Asian Healthcare Summit" held in Hong Kong attracted over 2,800 participants from more than 40 countries and regions, focusing on future development and cooperation opportunities in the global healthcare sector [1] - A key topic discussed was scientific anti-aging and achieving healthy aging in the context of the global "silver wave," with significant interest in the research on Ba Zi Bu Shen capsules based on traditional Chinese medicine [1][2] - The population aged 60 and above in China exceeded 300 million by the end of last year, accounting for 22% of the total population, highlighting the increasing health issues associated with aging [2] Group 2 - The theory of Qi Luo and the essence-spirit theory posits that the core of aging is "kidney essence deficiency," and "tonifying kidney essence" is crucial for anti-aging [2] - Ba Zi Bu Shen capsules have been shown to intervene in 10 biological markers of aging, including maintaining stem cell vitality and reducing telomere loss, aligning with recent findings in Western medicine [2] - A clinical study published in the journal "Phytomedicine" demonstrated that Ba Zi Bu Shen capsules significantly improved aging symptoms in participants aged 30 to 78 over a 12-week intervention, with a 76.7% increase in telomerase activity compared to the placebo group [3][4] Group 3 - The research on Ba Zi Bu Shen capsules shows significant systemic intervention effects on nine major bodily systems, including nervous, circulatory, and immune systems [4] - The Chinese government is actively supporting research in this area, with a key project focusing on the evaluation and integration mechanisms of traditional Chinese medicine for anti-aging [4] - The summit established a "Silver Health Chapter" to address the challenges of population aging, emphasizing the role of scientific research in traditional Chinese medicine as a bridge between Eastern and Western approaches to aging [5]

Group 1: Business Development Strategies - The company plans to enhance offline business through a distributor awakening program, multiple new product launches, and a diverse product SKU range [2] - For international expansion, the focus is on Southeast Asia, particularly the Indian market, leveraging the lifespace brand with localized operations [2] - The production model primarily relies on in-house manufacturing, with some new formulations using contract manufacturing [3] Group 2: Product Innovation and Launch - New product development involves market research, investment modeling, and management approval, with ongoing updates across major product categories [3] - The company is exploring the introduction of ergothioneine-related products based on market demand and business growth [3] - There is a commitment to high-quality product innovation in online channels, aiming for premium pricing and sustainable e-commerce models [3] Group 3: Sales Performance and Market Challenges - In Q1 of this year, sales for the products "健力多" and protein powder saw a significant decline compared to the previous year, attributed to changing consumer environments and industry dynamics [3] - Continuous strategy optimization is necessary to improve sales performance for these categories [3] Group 4: Regulatory and M&A Considerations - The company is monitoring online regulatory trends, which are expected to create favorable conditions for compliant businesses [3] - There is a cautious approach towards potential mergers and acquisitions, aligning with market conditions and strategic planning [3]